Regulatory Perspective, by Jeff Murray

AASLD Perspective, by Leonard Seeff

EASL Perspective, by Jean-Michel Pawlotsky

Recap of HCV DrAG Working Group Meetings, by Ann Kwong

EASL Preclinical Overview, by Filip Josephson 

FDA Preclinical Overview, by Peyton Myers 

Phase 1 and 2 Trial Design, by Donald Jensen and Panel Discussion 

Phase 3 Trial Design by Kimberly Struble and Panel Discussion 

Clinical Overview by Ira Jacobson and Panel Discussion 

HCV Resistance and Remaining Challenges, by Jean Michel Pawlotsky

Current Understanding of HCV Resistance and Treatment Failure with New DAAs, by Jean-Michel Pawlotsky and Panel Discussion

HIV/HCV Co-infected Patients, Patients with Decompensated Cirrhosis, Liver Transplant, and other Special Populations, by Mark Sulkowski and Panel Discussion

Current Drug Users and Patients in Opiate Substitution Therapy, by Tracy Swan and Panel Discussion

Considerations in Pediatric Populations and Early Access Protocols/Treatment INDs, by Kimberly Struble and Panel Discussion

Summary and Adjournment, by Veronica Miller